Clinical trials in Nice – page 15

971 clinical trials in Nice, France across 4 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in FranceEssaisCliniques.fr

Nice at a glance

971

clinical trials

Research sites4

Quick filters

971 trials in Nice

Open in trial search

Sarcoma+4

Recruiting

Study of zanidatamab in adult patients with HER2-positive solid tumors (endometrial, colorectal, head & neck, sarcoma) or HER2-mutant non-small cell lung cancer

InvestigationalNo placebo

Study of zanidatamab in adult patients with HER2-positive solid tumors (endometrial, colorectal, head & neck, sarcoma) or HER2-mutant non-small cell lung cancer

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years
Substances:Zanidatamab
Sponsor:Unicancer

Contact Research Centre

Acute myeloid leukaemia

Recruiting

Study of Bleximenib, Venetoclax, and Azacitidine Treatment for Newly Diagnosed Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy

Registered drug

Study of Bleximenib, Venetoclax, and Azacitidine Treatment for Newly Diagnosed Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Azacitidine
Sponsor:Janssen Cilag International

Contact Research Centre

Malignant melanoma

Recruiting

Study of mRNA-4157 and Pembrolizumab for Patients with Metastatic Melanoma

Registered drug

Study of mRNA-4157 and Pembrolizumab for Patients with Metastatic Melanoma

Registered drug

France

Participants:18–64 years · 65+ years
Substances:MRNA-4157
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Hypertrophic cardiomyopathy

Recruiting

Study Evaluating Direct Oral Anticoagulants for Prevention of Blood Clots in Patients with Hypertrophic Cardiomyopathy and Abnormal Left Atrial Function

Registered drugNo placebo

Study Evaluating Direct Oral Anticoagulants for Prevention of Blood Clots in Patients with Hypertrophic Cardiomyopathy and Abnormal Left Atrial Function

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Rivaroxaban
Sponsor:Centre Hospitalier Universitaire De Rennes

Contact Research Centre

Malignant melanoma

Recruiting

Vusolimogene Oderparepvec with Nivolumab for Advanced Melanoma Patients Whose Cancer Progressed After Previous Immunotherapy Treatments

Registered drugNo placebo

Vusolimogene Oderparepvec with Nivolumab for Advanced Melanoma Patients Whose Cancer Progressed After Previous Immunotherapy Treatments

Registered drugNo placebo

France

Participants:0–17 years · 18–64 years · 65+ years
Substances:Dacarbazine Citrate
Sponsor:Replimune Group Inc.

Contact Research Centre

Endometrial cancer

Recruiting

Study of Trastuzumab Deruxtecan, Rilvegostomig, and Pembrolizumab for Advanced or Recurrent Endometrial Cancer in HER2-Positive Patients

Registered drugNo placebo

Study of Trastuzumab Deruxtecan, Rilvegostomig, and Pembrolizumab for Advanced or Recurrent Endometrial Cancer in HER2-Positive Patients

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:AstraZeneca AB

Contact Research Centre

Glomerulonephritis membranous

Recruiting

Evaluating Dapagliflozin's Effect on Immune Activity in Patients with Membranous Nephropathy

Registered drugNo placebo

Evaluating Dapagliflozin's Effect on Immune Activity in Patients with Membranous Nephropathy

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Dapagliflozin
Sponsor:Centre Hospitalier Universitaire De Nice

Contact Research Centre

Psoriatic arthropathy

Recruiting

Study on Lutikizumab and Risankizumab for Adults with Active Psoriatic Arthritis

InvestigationalNo placebo

Study on Lutikizumab and Risankizumab for Adults with Active Psoriatic Arthritis

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years
Substances:Lutikizumab
Sponsor:AbbVie Deutschland GmbH & Co. KG

Contact Research Centre

Non-small cell lung cancer

Recruiting

Study of Sigvotatug Vedotin and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer with High PD-L1 Levels

Registered drugNo placebo

Study of Sigvotatug Vedotin and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer with High PD-L1 Levels

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Pembrolizumab
Sponsor:Pfizer Inc.

Contact Research Centre

Non-small cell lung cancer

Recruiting

Study Comparing Tepotinib to Standard Treatment for Patients with Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer

Registered drugNo placebo

Study Comparing Tepotinib to Standard Treatment for Patients with Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Atezolizumab
Sponsor:Intergroupe Francophone De Cancerologie Thoracique

Contact Research Centre

Chronic inflammatory demyelinating polyradiculoneuropathy

Recruiting

Study of DNTH103 Treatment for Adults with Chronic Inflammatory Demyelinating Polyneuropathy: Comparing Effectiveness with Placebo

Investigational

Study of DNTH103 Treatment for Adults with Chronic Inflammatory Demyelinating Polyneuropathy: Comparing Effectiveness with Placebo

Investigational

France

Participants:18–64 years · 65+ years
Substances:DNTH103
Sponsor:Dianthus Therapeutics Inc.

Contact Research Centre

Haematological malignancy+1

Recruiting

Study on Fecal Microbiota Transplantation to Prevent Complications in Patients After Stem Cell Transplant for Blood Cancer

InvestigationalNo placebo

Study on Fecal Microbiota Transplantation to Prevent Complications in Patients After Stem Cell Transplant for Blood Cancer

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years · Healthy volunteers
Substances:Allogeneic Faecal Microbiota
Sponsor:CHU Gabriel-Montpied

Contact Research Centre

Other cities in France

The busiest research cities in the country

All 382 cities in France

Clinical research in Nice

What the registry says about research in the country

01 Neurological Disorders

Innovative research focusing on neurodegenerative conditions and movement disorders, including trials evaluating new treatments for Amyotrophic Lateral Sclerosis and Essential Tremor.

ALS Treatment Development
Movement Disorder Therapies
Multiple Sclerosis Management

Studies aim to improve quality of life and slow disease progression through targeted therapeutic approaches.

02 Autoimmune Conditions

Comprehensive research into inflammatory disorders, including studies on Psoriatic Arthritis and innovative treatments for various autoimmune conditions.

Psoriasis Management
Inflammatory Disease Therapy
Myasthenia Gravis Treatment

Focus on developing targeted therapies and combination treatments for better disease control.

03 Oncology Research

Advanced studies in cancer treatment, particularly focusing on head and neck cancers and innovative approaches in lung cancer therapy.

Head and Neck Cancer Treatments
Neuroendocrine Carcinomas
Prostate Cancer Therapy

Investigating combination therapies and targeted treatments for improved patient outcomes.

04 Gastrointestinal Disorders

Groundbreaking research in inflammatory bowel diseases, including novel approaches for Crohn's Disease and Ulcerative Colitis treatment.

Microbiota Transplantation
IBD Management
Novel Therapeutic Approaches

Exploring innovative therapeutic strategies and microbiome-based treatments.

05 Infectious Disease Prevention

Critical research in HIV prevention and treatment, focusing on long-acting preventive medications and innovative therapeutic approaches.

HIV Pre-Exposure Prophylaxis
Long-Acting Treatments
Prevention Strategies

Development of new preventive measures and treatment options for at-risk populations.

Back to France All countries